{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:52:07Z","timestamp":1780098727798,"version":"3.54.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005918","name":"Christian Medical College, Vellore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ijmmb.2025.100885","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T02:42:14Z","timestamp":1748918534000},"page":"100885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["HIV vaccine \u2013 Is there a ray of hope in the rugged journey?"],"prefix":"10.1016","volume":"56","author":[{"given":"Gautam","family":"Barik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnanadurai John","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diviya","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Demosthenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7770-459X","authenticated-orcid":false,"given":"Rajesh","family":"Kannangai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2025.100885_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12977-018-0457-7","article-title":"HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth","volume":"15","author":"Van Schooten","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijmmb.2025.100885_bib2","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1016\/j.vaccine.2013.05.018","article-title":"A brief history of the global effort to develop a preventive HIV vaccine","volume":"31","author":"Esparza","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijmmb.2025.100885_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5840\/asce19931312","article-title":"The use of zairian children in HIV vaccine experimentation: a cross-cultural study in medical ethics","volume":"13","author":"Nairn","year":"1993","journal-title":"Annu Soc Christ Ethics"},{"key":"10.1016\/j.ijmmb.2025.100885_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/infdis\/168.6.1387","article-title":"Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection","volume":"168","author":"Belshe","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib5","first-page":"121","article-title":"Technology evaluation: HIVAC-1e","volume":"1","author":"Zheng","year":"1999","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.ijmmb.2025.100885_bib6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ijmmb.2025.100885_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/COH.0b013e328363d3b7","article-title":"Nonreplicating vectors in HIV vaccines","volume":"8","author":"Johnson","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijmmb.2025.100885_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.qai.0000248356.48501.ff","article-title":"Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial","volume":"44","author":"Russell","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijmmb.2025.100885_bib10","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/S2352-3018(21)00073-4","article-title":"A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials","volume":"8","author":"Zolla-Pazner","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijmmb.2025.100885_bib11","first-page":"438","article-title":"Ancestral and consensus envelope immunogens for HIV-1 subtype C","volume":"352","author":"Kothe","year":"2006","journal-title":"Virology (New York, N Y)"},{"key":"10.1016\/j.ijmmb.2025.100885_bib12","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijmmb.2025.100885_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/infdis\/jiac445","article-title":"Safety and immunogenicity of Ad26-vectored HIV vaccine with mosaic immunogens and a novel mosaic envelope protein in HIV-uninfected adults: a phase 1\/2a study","volume":"227","author":"Stieh","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijmmb.2025.100885_bib15","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijmmb.2025.100885_bib16","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1172\/JCI128699","article-title":"DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial","volume":"129","author":"Rouphael","year":"2019","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ijmmb.2025.100885_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciz1239","article-title":"Phase 1 human immunodeficiency virus (HIV) vaccine trial to evaluate the safety and immunogenicity of HIV subtype C DNA and MF59-adjuvanted subtype C envelope protein","volume":"72","author":"Hosseinipour","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25793","article-title":"Current approaches to HIV vaccine development: a narrative review","volume":"24","author":"Kim","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijmmb.2025.100885_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25831","article-title":"Strategies for induction of HIV\u20101 envelope\u2010reactive broadly neutralizing antibodies","volume":"24","author":"Williams","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.ijmmb.2025.100885_bib20","article-title":"Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core","volume":"7","author":"Borst","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.ijmmb.2025.100885_bib21","doi-asserted-by":"crossref","first-page":"eadf3309","DOI":"10.1126\/scitranslmed.adf3309","article-title":"A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses","volume":"15","author":"Cohen","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijmmb.2025.100885_bib22","first-page":"483","article-title":"HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity (Camb, Mass)"},{"key":"10.1016\/j.ijmmb.2025.100885_bib23","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.xphs.2019.01.033","article-title":"Developability assessment of physicochemical properties and stability profiles of HIV-1 BG505 SOSIP.664 and BG505 SOSIP.v4.1-GT1.1 gp140 envelope glycoprotein trimers as candidate vaccine antigens","volume":"108","author":"Whitaker","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijmmb.2025.100885_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.61","article-title":"Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults","volume":"3","author":"Mutua","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ijmmb.2025.100885_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1086\/428405","article-title":"Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial","volume":"191","author":"Gilbert","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"Robb","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib27","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijmmb.2025.100885_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/infdis\/jix099","article-title":"Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial","volume":"215","author":"Rerks-Ngarm","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijmmb.2025.100885_bib29","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2352-3018(19)30406-0","article-title":"Late boosting of the RV144 regimen with AIDSVAX B\/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial","volume":"7","author":"Pitisuttithum","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijmmb.2025.100885_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1089\/aid.2007.0292","article-title":"A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine","volume":"24","author":"Mehendale","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijmmb.2025.100885_bib31","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1089\/aid.2009.0096","article-title":"A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers","volume":"25","author":"Ramanathan","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijmmb.2025.100885_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055831","article-title":"Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers","volume":"8","author":"Mehendale","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijmmb.2025.100885_bib33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","article-title":"Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies","volume":"23","author":"Haynes","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijmmb.2025.100885_bib34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s13238-018-0534-7","article-title":"The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ijmmb.2025.100885_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41577-018-0103-6","article-title":"Advancing an HIV vaccine; advancing vaccinology","volume":"19","author":"Burton","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijmmb.2025.100885_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.chom.2020.01.027","article-title":"VRC34-Antibody lineage development reveals how a required rare mutation shapes the maturation of a broad HIV-neutralizing lineage","volume":"27","author":"Shen","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijmmb.2025.100885_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijmmb.2025.100885_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/QAI.0000000000002649","article-title":"A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa: baseline findings","volume":"87","author":"Mgodi","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijmmb.2025.100885_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2384460","article-title":"Biotech's role in advancing HIV vaccine development","volume":"13","author":"Tatoud","year":"2024","journal-title":"Emerg Microb Infect"},{"key":"10.1016\/j.ijmmb.2025.100885_bib40","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1089\/aid.2014.5052a.abstract","article-title":"Hvtn 097: evaluation of the RV144 vaccine regimen in HIV uninfected South African adults","volume":"30","author":"Gray","year":"2014","journal-title":"AIDS Res Hum Retrovir"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085725000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085725000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:17:32Z","timestamp":1756153052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085725000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"alternative-id":["S0255085725000982"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2025.100885","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV vaccine \u2013 Is there a ray of hope in the rugged journey?","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2025.100885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100885"}}